AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 22 min read$TEM

Tempus: Q3 Earnings Snapshot

Tempus AI Inc. (TEM) reported a Q3 loss of $14.9 million, or 8 cents per share, but adjusted earnings of 7 cents per share, beating estimates. Revenue was $411.5 million, also exceeding forecasts. The company expects full-year revenue of $1.6 billion to $1.61 billion.

Original reporting
finance.yahoo.com
Published Nov 2, 2026, 12:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 12:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Tempus: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

Earnings beat may trigger short‑term price rally, but underlying loss and modest guidance temper upside.

02

Market read

First‑time earnings disclosure with beat on loss and revenue; likely short‑term catalyst for the stock.

03

What to watch

Guidance for full‑year revenue $1.6‑1.61B suggests modest growth; investors should watch cash burn.

Relevance 8/10Novelty 8/10Timing: after-hours reaction

Background

Tempus AI is a Chicago‑based health‑care technology company providing AI‑driven data solutions for oncology.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Tempus AI reported Q3 loss of $14.9M and revenue of $411.5M, both beating analyst expectations.

Expected impact

potential upside as market prices in the earnings beat

Evidence & confidence

Surprise earnings beat often triggers short-term buying pressure.

Market effects

Sector

Health‑care technology earnings beat may lift peer stocks in the sector.

Regional

U.S. market participants may adjust exposure to AI‑driven health‑tech firms.

Global

Limited to U.S. and global health‑tech investors.

Counterpoint

What could challenge this read

The loss per share, though better than expected, remains negative; risk‑averse traders may stay cautious.

Key entities

  • Company
    Tempus AI Inc.

    Health‑care technology firm reporting Q3 results.

Read at source← All news

StoryTempus AI posts record Q3 revenue, first adjusted profit and raises full‑year outlook

Also covered by

6 outlets

Related articles

NOV 3
$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

investing.com2 min
NOV 3
$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.

finance.yahoo.com2 min
NOV 2
$TEMMedAI 8/10

Tempus AI (TEM): Oncology Volume Surge and Data Licensing Bookings Signal a Profitable Inflection

Tempus AI (TEM) reported Q3 2026 revenue of $411.5M, up 23% YoY, with adjusted EBITDA of $25.6M. Oncology revenue grew 28% to $172.6M, while Data and Applications revenue increased 33% to $108.1M. The company raised full-year revenue guidance to $1.60B-$1.605B and expects near-term catalysts from reimbursement improvements and the pending $1.7B Personalis acquisition.

news.alphastreet.com7 min